公司資料
ARS Pharmaceuticals 股價、新聞與催化劑
- 股票代碼:
- SPRY
- 交易所:
- NASDAQ
- 產業:
- Biopharma
- 所在地:
- United States
股票表現
6.24 USD (+10.44%)
收盤價
最後更新: 2026年8月17日
884M USD
市值
股價為何變動
As of Aug 17, 2026, SPRY closed up 10.4% at $6.24. No new same-company headline was identified in the current news window.
公司概覽
Needle-Free Epinephrine Company
ARS Pharmaceuticals commercializes neffy, an epinephrine nasal spray for Type I allergic reactions, including anaphylaxis. Neffy is an approved needle-free emergency epinephrine treatment in the United States and European Union.
Neffy Commercialization
The company is building U.S. sales, payer access, prescription-refill programs, and pharmacy affordability support while expanding internationally through regional partners. Health Canada has approved neffy, with ALK responsible for Canadian commercialization.
Patient-Centered Delivery Strategy
The nasal formulation is intended to remove barriers associated with injectable epinephrine, including needle anxiety, complex administration, and hesitation during emergencies. ARS is building its commercial strategy around portability, ease of use, and broader willingness to carry treatment.
Intranasal Epinephrine Platform Expansion
Beyond emergency allergy treatment, ARS is evaluating intranasal epinephrine for acute flares of chronic spontaneous urticaria and has advanced the program into a Phase 2b study.
International Partnership Model
ARS uses regional partners to extend neffy beyond its direct U.S. commercial organization. These partners assume responsibility for local regulatory, distribution, and launch activities while broadening the geographic value of the product.
未來催化劑
- Interim Phase 2b data for intranasal epinephrine in chronic spontaneous urticaria in the first quarter of 2027.
近期新聞
- 01
- 02
- 03
- 04
- 05
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。